Department of Radiology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 56, Dongsu-ro, Bupyeong-gu, Incheon, 21431, Republic of Korea.
Cardiovasc Intervent Radiol. 2019 Aug;42(8):1199-1203. doi: 10.1007/s00270-019-02237-2. Epub 2019 May 9.
We evaluated the safety and efficacy of transhepatic tract embolisation after a biliary intervention using n-butyl cyanoacrylate (NBCA) and autologous blood.
Between January 2017 and December 2018, 42 consecutive patients (mean age: 71 ± 15 years, 24 men) with malignant (n = 26) or benign (n = 16) biliary obstructions underwent percutaneous biliary intervention followed by tract embolisation within 2 weeks. Forty-six transhepatic tracts (4 bilateral) in 42 patients were embolised using a NBCA and lipiodol mixtures (1:1-1:2 ratios) after intraductal infusion of peripherally obtained autologous blood. The indwelling catheter diameters were 8.5-14 Fr. The median interval between percutaneous biliary drainage and tract embolisation was 10 days (range 3-14 days). Glue-cast formation via fluoroscopy and immediate complications were reviewed retrospectively in medical records. Follow-up data (median: 135, range 11-720 days) including computed tomography (CT) images (n = 17) were evaluated for delayed complications and glue-cast formation.
Successful glue-cast formations were achieved in all 46 tracts. No patients experienced haemorrhage, and only one patient had external bile leakage. Eight patients complained of abdominal pain (numerical scale ≤ 5) immediately after embolisation, which was controlled by analgesics. Two patients had transient fever. Segmental (n = 11) or sub-segmental (n = 6) glue-cast patterns were identified along the transhepatic tract by follow-up CT. No biliary obstructions were caused by inadvertent glue spread. Fragmented glue was detected outside the stent in one patient.
Transhepatic parenchymal tract embolisation with NBCA and autologous blood is a safe and feasible method for preventing bile leakage.
Level 4, Case Series.
我们评估了经皮肝胆管介入治疗后使用氰基丙烯酸正丁酯(NBCA)和自体血进行经肝实质通道栓塞的安全性和疗效。
2017 年 1 月至 2018 年 12 月,42 例连续的恶性(n=26)或良性(n=16)胆道梗阻患者接受了经皮肝胆管介入治疗,随后在 2 周内进行了经肝实质通道栓塞。42 例患者的 46 个经肝通道(4 个双侧)采用 NBCA 和碘油混合物(1:1-1:2 比例)经导管内输注外周获得的自体血后进行栓塞。留置导管直径为 8.5-14 Fr。经皮肝胆管引流与经肝实质通道栓塞之间的中位间隔时间为 10 天(范围 3-14 天)。回顾性查阅病历记录以评估透视下胶铸形成和即时并发症。对包括计算机断层扫描(CT)图像(n=17)在内的随访数据(中位数:135 天,范围 11-720 天)进行评估以了解迟发性并发症和胶铸形成情况。
所有 46 个通道均成功形成胶铸。无患者发生出血,仅 1 例发生胆汁外漏。8 例患者(数字评分≤5)在栓塞后立即出现腹痛,经止痛剂控制。2 例患者出现短暂发热。17 例患者中的 11 例存在节段性和 6 例亚节段性胶铸模式。没有因意外胶扩散而导致胆道梗阻。1 例患者的支架外检测到碎胶。
经皮肝胆管介入治疗后使用 NBCA 和自体血进行经肝实质通道栓塞是一种安全可行的预防胆漏的方法。
4 级,病例系列。